Hidden health benefits from weight-loss jabs revealed
The research also suggests that individuals with type 2 diabetes and obesity who are prescribed these medications could face a reduced risk of premature death.
Academics behind the study noted that while the efficacy of GLP agonist drugs – such as semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro) – in managing weight and blood sugar levels is widely recognised, their wider health benefits have remained less understood.
The comprehensive study, conducted by experts in Taiwan, examined data from 60,000 people worldwide, with an average age of 58, all diagnosed with type 2 diabetes and obesity.
Roughly half of the participants were given GLP agonist drugs.
These medications function by curbing appetite, slowing digestion, reducing the liver's sugar output, and enhancing the body's insulin production when required.
The other half used other anti-diabetic medication.
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37 per cent lower risk of dementia and a 19 per cent reduced risk of stroke.
They were also 30 per cent less likely to die during the follow-up period.
When researchers looked at the data further, they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
When I lost 3 STONE in 3 WEEKS through a free method better than any fat jab, I reversed my pre-diabetes. So did I put it back on? Six months on DONAL MACINTYRE reveals all... and says anyone can do it
Six months ago, I took a leap into the unknown. In a desperate bid to reclaim my health and shed the weight I had carried for far too long, I did something most would consider mad: I stopped eating. Not for a day, or a week — but for 23 days. No food. Just water, black coffee and sheer determination.
Reuters
2 hours ago
- Reuters
FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy
July 25 (Reuters) - The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' (SRPT.O), opens new tab muscular disorder gene therapy Elevidys. The death occurred on June 7, the agency said, sending shares of the company down more than 3% in extended trading. The patient with Duchenne muscular dystrophy, who died in Brazil, was treated with Elevidys but was not a participant in a clinical trial, Roche, which partners with Sarepta outside the U.S., told Reuters in an email. The reporting physician has assessed the death as unrelated to treatment with the gene therapy, Roche said, adding that the death was reported to the health authorities as required per local regulations, and that it was continuing to gather and analyze the information from this event. Sarepta has come under intense regulatory scrutiny after two non-ambulatory teenage boys died due to acute liver failure associated with Elevidys, and a 51-year-old man who had received its experimental gene therapy SRP-9004 died from the same condition. Late on Monday, the company said it would comply with a request from the FDA to pause all shipments of Elevidys in the United States. Its partner Roche also paused Elevidys shipments in some countries outside the U.S. later. The FDA's request had come after the company disclosed the death of the patient on SRP-9004.
Daily Mail
4 hours ago
- Daily Mail
'Aggressive mandate' of Covid vaccines was 'probably a bad idea' as new study reveals WHO mandated blanket vaccination saved 'fewer lives than expected'
The 'aggressive mandate' of Covid vaccines has been blasted as a 'bad idea' by experts after a new study revealed it saved less lives than predicted. The World Health Organisation (WHO) claimed that the jabs prevented 14.4million deaths just in the first year, with some estimating up to 20million. However, new research by Stanford University and Italian doctors revealed the true number is closer to 2.5million. The team estimated that nine out of ten prevented deaths were in the over-60s, while it only saved 299 people under the age of 20 and 1,808 youngsters between 20 and 30 globally. John Ioannidis, Professor of Medicine at Stanford University and the first author, said: 'Targeting the populations who would get the vast majority of the benefit and letting alone those with questionable risk-benefit and cost-benefit makes a lot of sense. 'Aggressive mandates and the zealotry to vaccinate everyone at all cost were probably a bad idea.' Overall 5,400 people needed to be vaccinated to save one life but in the under-30s this figure rose to 100,000 jabs, the paper suggests. The over-70s made up nearly 70 per cent of the lives saved, while the 60 to 70s accounted for a further 20 per cent. Meanwhile, under-20s made up just 0.01 per cent of lives saved and 20 to 30s were 0.07 per cent Researchers concluded that although vaccines had a 'substantial benefit' on global mortality, it was 'mostly limited' to older people. More than 23 billion doses of the vaccine have been administered since its roll out in 2021. But there have been growing concerns over its harms, particularly for young people, and how it may not be worth it for a population who is at the lowest risk of death. US scientists from Yale University identified an alarming syndrome linked to mRNA jabs, those made by the likes of Pfizer and Moderna. Called 'post-vaccination syndrome', the condition appears to cause brain fog, dizziness, tinnitus and exercise intolerance, the researchers reported. Some sufferers also show distinct biological changes, including differences in immune cells and the presence of coronavirus proteins in their blood, years after taking the shot. The condition is also said to increase the risk of reawakening a dormant virus called Epstein-Barr, which can cause flu-like symptoms, swollen lymph nodes and nerve issues. In June, manufacturers added warnings for myocarditis and pericarditis - a potentially dangerous inflammation of the heart muscle It comes as more than 17,000 Brits now claim they have been injured or have had loved ones killed by a Covid jab, according to the latest Government data.
